On a quiet Columbus Day, on Bloomberg it was announced that Allscripts Healthcare Solutions
HealthCor Management LP, which held 7.4% of the common stock outstanding as of June 30, sued Allscripts in May after the board shakeup. New York-based HealthCor dropped the lawsuit a month later when Allscripts agreed to nominate three independent directors to the board.
Another notable event that might have been a catalyst for this possible takeout is that Allscripts lost a bid for a $302 million contract to supply its technology to New York city's public hospitals on September 27th.
Also, to be noted, MDRX is the worst performer of 33 companies in the S&P Midcap Healthcare Index in 2012, falling 30%. In terms of valuation, the stock is trading at $13.9 versus its 52-week range of $8.84-$21.66, and at a trailing-12-month EV/EBITDA multiple of 10 times. Although we don't have more details on the possible takeover bid, the best comparison for this takeover would be the Emdeon deal in 2011, which occurred at 11 times trailing EBITDA, which implies a $15-$16 buyout for Allscripts. Emdeon was acquired by Blackstone in August 2011 for $3 billion, including debt.
The top holders of Allscripts stock include Manning Napier Advisors (9.35%), HealthCor Management (7.5%), BlackRock (6.7%), and Wellington Management (6.15%).
Given where Allscripts is trading versus its best takeout peer Emdeon, there seems to be no reason to run after this stock. That being said, we can take a look at candidates in the space depicted by Kapitall's Compar-O-Matic below:
Written by Kapitall's Sabina Bhatia.